A Baltimore judge was set to hear objections Friday to a preliminary $190 million dollar settlement between Johns Hopkins Hospital System and more than 8,000 patients of a gynecologist who used tiny cameras to secretly photograph women and girls during examinations.
The addition significantly expands PCI's presence in the UK/EU to support global investigational...
The objectives of the contract are to advance the development of Soligenix's thermostabilization...
Merck KGaA today announced that the Board of Partners has promoted Stefan Oschmann to the position of Deputy CEO and Vice Chairman of the Executive Board. Concurrently, Belén Garijo was appointed to the Executive Board to take over leadership for the Pharma business.
Elanco, the animal health division of Eli Lilly and Company, and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, are announcing a strategic R&D agreement that will focus on developing integrated solutions to enable livestock producers to increase meat and milk production to meet the demands of the growing global population.
German pharmaceuticals and chemicals company Bayer AG says it plans a separate stock listing for its polymer division. The Leverkusen-based company that invented aspirin said Thursday the move would be part of an effort to focus the group on its health care and crop science businesses.
Merck and Sun Pharmaceutical Industries have announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis.
The board of Auxilium Pharmaceuticals has adopted a "poison pill" shareholder rights plan to ward off a hostile takeover after Endo International PLC announced an unsolicited offer worth about $1.41 billion for its fellow drugmaker.
A Detroit-area cancer doctor accused of putting people through unnecessary treatments and then billing insurers for millions of dollars pleaded guilty to fraud Tuesday, admitting that he knew his patients often didn't need chemotherapy.
EMD Serono and Sutro Biopharma announced a collaboration and license agreement to develop antibody drug conjugates (ADCs). ADCs are composed of an antibody linked to a cytotoxic drug. The antibody is thought to specifically target and deliver the cytotoxic drug to the cancer cells.
Endo International PLC says it is making an unsolicited offer for Auxilium Pharmaceuticals that values Auxilium at $28.10 per share. The deal is worth $1.41 billion in cash and stock, based on Auxilium's shares outstanding. Endo values the offer at $2.2 billion.
Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.
MedGenesis Therapeutix has entered into an agreement with Pfizer, granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson's disease.
Mylan today announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's Advair Diskus and its insulin analog to Sanofi's Lantus. In October 2014, Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.
In an increasingly complex and challenging climate, chemical companies are facing a combination of shifting market forces and an increasingly heterogeneous customer set. Many organizations are focusing solely on all-out growth or across-the-board cost-cutting strategies in an attempt to adjust course.
AstraZeneca and Eli Lilly announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.
Allergan and Pershing Square are agreeing on at least one step toward settling a fight over the makeup of the Botox-maker's board. Allergan will hold special shareholders meeting, as Pershing Square and its partner, Valeant Pharmaceuticals, continue their push for control of the drugmaker.
New York's attorney general filed a federal lawsuit Monday seeking to stop a manufacturer from discontinuing its drug widely used to treat Alzheimer's patients, arguing the company is illegally driving patients to its newer patented drug to avoid losses from cheaper generic alternatives coming out next year.
Shares of Avanir Pharmaceuticals soared Monday after the company reported positive clinical trial results for a drug that is designed to treat agitation in Alzheimer's disease patients. The company said patients who were treated with AVP-923 were less agitated than patients given a placebo.
The Food and Drug Administration is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use skin shocks as aversive conditioning for aggressive patients.
High level efforts are underway to find ways to substantially ramp up production of experimental Ebola vaccines and drugs, officials at the World Health Organization and within the U.S. government say.
Vernalis and Tris Pharma announced that the FDA has confirmed that the New Drug Application for Tuzistra XR has been accepted for full review. This triggers a milestone payment from Vernalis to Tris.
Gilead Sciences says it has reached a deal with several generic drugmakers to produce cheaper versions of its popular, expensive hepatitis C drug Sovaldi for use in developing countries.
The powerful chemical industry is putting its lobbying muscle behind legislation that would establish standards for chemicals used in products from household goods to cellphones and plastic water bottles — but also make it tougher for states to enact their own regulations.
The Department of Justice filed a court motion against the German conglomerate over its advertisements for Phillips' Colon Health, which claims to prevent diarrhea, constipation, gas and bloating. Federal officials say the company does not have reliable scientific evidence to support those claims.
The Livestrong cancer charity is reporting a sharp drop in donations and revenue after founder Lance Armstrong admitted taking performance-enhancing drugs during most of his record-setting cycling career.
The University of Pennsylvania today reached an important milestone in its alliance with Novartis as it unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia.
Oxygen Biotherapeutics has elected to stop the current Phase IIb trial for its Oxycyte drug candidate and consider strategic alternatives for the program moving forward. The company will review the data generated on the patients enrolled in the trial to date.
- Page 1